OBJECTIVES: To reach consensus with recommendations made by an OMERACT Special Interest Group (SIG). METHODS: Rheumatologists and industry representatives interested in gout rated and clarified, in three iterations, the importance of domains proposed by the OMERACT SIG for use in acute and chronic gout intervention studies. Consensus was defined as a value of less than 1 of the UCLA/RAND disagreement index. RESULTS: There were 33 respondents (61% response rate); all agreed the initial items were necessary, except "total body urate pool". Additional domains were suggested and clarification sought for defining "joint inflammation" and "musculoskeletal function". Items that demonstrated no clear decision were re-rated in the final iteration. There were six highly rated items (rating 1-2) with four slightly lower rating items (rating 3) for acute gout; and 11 highly rated items with eight slightly lower ratings for chronic gout. CONCLUSIONS: Consensus is that the following domains be considered mandatory for acute gout studies: pain, joint swelling, joint tenderness, patient global, physician global, functional disability; and for chronic gout studies: serum urate, gout flares, tophus regression, health-related quality of life, functional disability, pain, patient global, physician global, work disability and joint inflammation. Several additional domains were considered discretionary.
OBJECTIVES: To reach consensus with recommendations made by an OMERACT Special Interest Group (SIG). METHODS: Rheumatologists and industry representatives interested in gout rated and clarified, in three iterations, the importance of domains proposed by the OMERACT SIG for use in acute and chronic gout intervention studies. Consensus was defined as a value of less than 1 of the UCLA/RAND disagreement index. RESULTS: There were 33 respondents (61% response rate); all agreed the initial items were necessary, except "total body urate pool". Additional domains were suggested and clarification sought for defining "joint inflammation" and "musculoskeletal function". Items that demonstrated no clear decision were re-rated in the final iteration. There were six highly rated items (rating 1-2) with four slightly lower rating items (rating 3) for acute gout; and 11 highly rated items with eight slightly lower ratings for chronic gout. CONCLUSIONS: Consensus is that the following domains be considered mandatory for acute gout studies: pain, joint swelling, joint tenderness, patient global, physician global, functional disability; and for chronic gout studies: serum urate, gout flares, tophus regression, health-related quality of life, functional disability, pain, patient global, physician global, work disability and joint inflammation. Several additional domains were considered discretionary.
Authors: Paula R Williamson; Douglas G Altman; Heather Bagley; Karen L Barnes; Jane M Blazeby; Sara T Brookes; Mike Clarke; Elizabeth Gargon; Sarah Gorst; Nicola Harman; Jamie J Kirkham; Angus McNair; Cecilia A C Prinsen; Jochen Schmitt; Caroline B Terwee; Bridget Young Journal: Trials Date: 2017-06-20 Impact factor: 2.279
Authors: Lisa K Stamp; Puja P Khanna; Nicola Dalbeth; Maarten Boers; Walter P Maksymowych; H Ralph Schumacher; Michael A Becker; Patricia A MacDonald; N Lawrence Edwards; Jasvinder A Singh; Lee S Simon; Fiona M McQueen; Tuhina Neogi; Angelo L Gaffo; Vibeke Strand; William J Taylor Journal: J Rheumatol Date: 2011-07 Impact factor: 4.666
Authors: Nicola Dalbeth; Fiona M McQueen; Jasvinder A Singh; Patricia A MacDonald; N Lawrence Edwards; H Ralph Schumacher; Lee S Simon; Lisa K Stamp; Tuhina Neogi; Angelo L Gaffo; Puja P Khanna; Michael A Becker; William J Taylor Journal: J Rheumatol Date: 2011-07 Impact factor: 4.666
Authors: Nicola Dalbeth; Cathy S Zhong; Rebecca Grainger; Dinesh Khanna; Puja P Khanna; Jasvinder A Singh; Fiona M McQueen; William J Taylor Journal: J Rheumatol Date: 2013-12-15 Impact factor: 4.666
Authors: Jasvinder A Singh; Shuo Yang; Vibeke Strand; Lee Simon; Anna Forsythe; Steve Hamburger; Lang Chen Journal: Ann Rheum Dis Date: 2011-07 Impact factor: 19.103